TP53 and acute myeloid leukemia: No significant difference in outcome was observed in AML‐MRC patients when (A) stratifying patients by number of TP53 mutations, (B) stratifying TP53MUT patients by the presence/absence of cytogenetic loss of TP53, or (C) stratifying patients by the number of TP53 hits.